Dr. Lina Souan

Chief Quality Officer & Deputy Director of KHCCBIO Cancer Biobank

Dr. Lina Souan, M.Sc., Ph.D., D-ABMLI is an Immunologist.  Dr. Souan received her M.Sc. in Molecular Immunology in 1996 from Pittsburgh University school of Medicine and her PhD in Immunology in 2001. She completed her first post-doctoral fellowship in stem cell therapy for cancer (2001 - 2003) at the Mayo Clinic stem cell lab, Rochester, MN, and the second post-doctoral fellowship was in Cancer Immunology Drug Discovery Research (2003 - 2004) at Sopherion Therapeutics, New Haven, CT.

Since 2004, she is the Head of Immunology Laboratory, Deputy Director and Chief Quality Officer of KHCCBIO Cancer Biobank since 2011, and the R&D Director at the Department of Pathology and Laboratory Medicine, King Hussein Cancer Center. She is a diplomat of the American Board of Medical Laboratory Immunology (ABMLI), and a fellow of the Association of Medical Laboratory of Immunologists (AMLI) since 2016; a contributing member in the American Society for Microbiology (ASM) since 2016. A member in the Jordan Society for Medical Laboratory Sciences since 2008 and a member supportive in the Jordanian Society of Allergy & Immunology since 2010 and a member in the American Association of Bioanalysts (AAB). She is an Expert and member in the internationally recognized-Union for International Cancer Control (UICC) review committee since 2018.

She has published several peer-reviewed articles, in addition to a book chapter titled “Innovative Approaches in Quality Management in Clinical Laboratories”. Dr. Souan is also a member in the international patent on discovering new Anti-Angiogenic Peptides and Methods of Use Thereof.

As the Director of research and development at King Hussein Cancer Center, Dr. Souan oversees several research grants focused on the immune response to COVID-19 and its vaccines in cancer patients and the Jordanian population as well as early detection of cellular response to CMV infections in transplant patients. Dr. Souan was awarded several national and international grants such as the grant awarded by the European Commission; CORDIS-FP7; part of the Seventh Framework Program (FP7) Capacities, and established the first ISO-compliant Cancer Biobank for Jordan and its Neighboring Countries through Knowledge Transfer and Training 2011-2014. The first of its kind in the Kingdom.  Amount:    €549,842. She was also awarded a grant from Abdul Hameed Shoman Foundation Innovation Award (AHSF-IA) – in response for COVID-19. Abdul Hameed Shoman Foundation for Innovation Award is the largest innovation award in the Kingdom. Amount: 20,000 JD.

16:15 – 16:30

Tuesday SESSION 7

Establishing the first COVID-19-Convalescent plasma biobank in Jordan. An update on the super valence rates to COVID-19 among KHCC- healthcare workers & blood bank donors.